Garrison Michael David sold $160K of BDX

BD (BDX) reported nine-month results from the iliac cohort of the AGILITY trial for its Revello Vascular Covered Stent, meeting primary endpoints with a 2.8% failure rate. The study showed 97.2% primary patency and 98.3% freedom from revascularization, with no device-related deaths. The stent is CE marked but investigational in the U.S. BD completed enrollment in the study’s superficial femoral and proximal popliteal artery cohort in August.

BD (NYSE: BDX) reported positive nine-month results from the AGILITY trial for its Revello™ Vascular Covered Stent, showing high vessel patency and low reintervention rates in treating iliac artery disease. The study met its primary endpoint with a 2.8% failure rate, and patients showed improved mobility and symptoms. The trial is ongoing, with follow-up through 36 months. The device is CE marked but remains investigational in the U.S.

Becton Dickinson (BDX) plans a $19B U.S. investment over several years, including $3B for manufacturing expansion, under a tariff relief agreement with the federal government. The company aims to increase U.S. production of essential medical consumables, with all needles made domestically. Tariff relief is contingent on meeting agreed milestones. The Trump administration has yet to finalize the tariff rule.

Becton, Dickinson and Company (BDX) announced a $19 billion investment to expand U.S. medical manufacturing, partnering with the U.S. government. The plan includes $3 billion for facility expansions and aims to increase domestic production of medical consumables by 5 billion units annually. The company will use American steel for all needles and is exempt from future Section 232 tariffs on specified products. BDX shares rose 2.06% to $184.38 on the news.

Becton Dickinson agreed to invest $19 billion in the U.S. over several years, including $3 billion for expanding domestic manufacturing, in exchange for future tariff relief. The company plans to increase U.S. production of medical consumables and needles, aiming for 80% domestic supply. President Trump announced medical device tariffs by year-end. The financial impact of the deal is not yet quantified.

Becton Dickinson (BD) agreed with the US government to invest $19 billion in domestic manufacturing over several years, securing future tariff relief. The company plans to expand US production of essential medical consumables by 5 billion annually, increasing domestic supply to 80%. BD will also manufacture all US needles domestically using American steel.